ANKRD17

Across TCGA pan-cancer cohorts, ANKRD17 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANKRD17 data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ANKRD17 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKRD17 expression acts as an unfavorable survival marker, although some lineages such as COAD and CCRCC show a favorable association.

COAD, PDAC, and LSCC are the cancer types where ANKRD17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.888	.023	30	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	13	view →
LSCC	DFS	Median	All	0.405	0.911	.002	12	view →
CCRCC	DFS	Tertile	II,III,IV	0.861	0.531	.023	7	view →
LUAD	DFS	Quartile	III,IV	0.767	0.363	.019	6	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.894	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANKRD17–COAD (DFS)

Open the COAD breakdown →